WUXI APPTEC held strong! Achieved 2024 performance guidance, expecting to achieve double-digit growth in revenue this year | Interpretations

In 2024, WUXI APPTEC's revenue and net profit saw a slight decline year-on-year, but it still achieved the performance guidance set at the beginning of last year; Despite the ongoing disturbances from the "Biotechnology Safety Act", customers and Orders still experienced substantial growth in 2024; WUXI APPTEC expects to achieve double-digit growth of 10-15% this year.

cls.cnMar 17 11:44 ET

0.124 billion USD! FOSUN PHARMA and United Family Healthcare "completely part ways" | Quick announcement.

① FOSUN PHARMA's subsidiary plans to sell a 6.6% stake in the symbol company for 0.124 billion USD; ② The relationship between FOSUN PHARMA and Huameijia can be traced back to 2009; ③ After this Trade is completed, FOSUN PHARMA will completely exit Huameijia.

cls.cnMar 13 11:26 ET

It's adding insult to injury! JiangSu WuZhong Pharmaceutical Development is beset by three major Bearish factors. Will the agency rights for Tongyan needles change? | Quick Announcement

① JiangSu WuZhong Pharmaceutical Development is currently facing uncertainties such as allegations of violating information disclosure laws, subsidiary's alleged assistance in tax fraud, and changes in agency rights for AestheFill within China. ② Compared to the beginning of the year, the company's stock price has fallen over 35%, reaching a new low for this year.

cls.cnMar 12 10:49 ET

JiangSu WuZhong Pharmaceutical Development is in trouble! A subsidiary has been sued for assisting in a tax fraud case and is also under investigation for violation of information disclosure regulations.

① JiangSu WuZhong Pharmaceutical Development announced that its subsidiary and the Chairman are being prosecuted for assisting in tax fraud of 0.242 billion yuan, and are also being investigated by the Securities Regulatory Commission for information disclosure violations, which may pose a risk of (Delisted); ② although the two incidents are closely timed, legal experts say that no correlation can be discerned at present; ③ since the third quarter of last year, JiangSu WuZhong's performance has shown significant improvement; ④ some investors have declared "they will protect their legitimate rights and interests" due to the significant fluctuations in stock prices.

cls.cnMar 7 10:07 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

AI helps reduce costs and improve efficiency in drug development. The "AI+Medical" Industry has explosive growth opportunities.

China Post Securities pointed out that the Global market size for AI+Medical industry AI solutions is expected to increase from 13.7 billion dollars in 2022 to 155.3 billion dollars in 2030, with a CAGR of 35.5%, indicating explosive growth opportunities in the industry.

cls.cnFeb 27 19:05 ET